

October 23, 2015



PharmaCyte Biotech Management Interviewed to Discuss Key Aspects of New Pancreatic Cancer Clinical Trial Design

SILVER SPRING, Md., Oct. 23, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box[®], announced today the release of a recorded interview with Chief Executive Officer Kenneth L. Waggoner and Chief Operating Officer Dr. Gerald W. Crabtree that highlights the key aspects of PharmaCyte's new pancreatic cancer clinical trial design.

Listen to the interview here: http://www.stockmarketmediagroup.com/wp-content/uploads/2015/10/PharmaCyte_Biotech_CEO_Interview.mp3

The interview walks the audience through PharmaCyte's last three press releases that announce the change in its clinical trial design. In the interview, PharmaCyte's Chief Executive Officer and Chief Operating Officer discuss PharmaCyte's efforts to address an unmet medical need with PharmaCyte's pancreatic cancer treatment, why the trial was moved to the United States under the direction of Translational Drug Development (TD2) and some of the specifics related to the new trial design.

About PharmaCyte Biotech

PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as "Cell-in-a-Box[®]". This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed.

PharmaCyte's treatment for cancer involves encapsulating genetically modified live cells capable of converting an inactive chemotherapy drug (ifosfamide) into its active or "cancer-killing" form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, ifosfamide is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the drug takes place at the source of the cancer without any side effects from the chemotherapy. This "targeted chemotherapy" has proven remarkably effective and safe to use in past clinical trials.

In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to

encapsulate a human cell line that has been genetically engineered to produce, store and secrete insulin at levels in proportion to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box[®] technology.

Safe Harbor

This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte's intellectual property and PharmaCyte's continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.

More information about PharmaCyte can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.

Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com



Source: PharmaCyte Biotech, Inc.